The aim of this work is to produce recommendations on the management of allogeneic stem
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …

Interferon alpha (IFN-α) has been used for over 30 years to treat myeloproliferative
neoplasms (MPNs). IFN-α was shown to induce clinical, hematological, molecular and …

Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

Abstract TP53 mutations (TP53 MTs) have been associated with poor outcomes in various
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …

Accelerated-phase myelofibrosis, currently defined by circulating blasts 10% to 19%, usually
confers very high risk for progression and poor outcome. The outcome of hematopoietic …

Background The calreticulin (CALR) exon 9 mutations that are identified in 20% of patients
with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) …

Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …

This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched
donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow …

We screened 136 patients with myelofibrosis and a median age of 58 years who underwent
allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F …